

Subject: FW: Update to USAMRAA's COVID-19 Guidance for Grants & Cooperative Agreements

Version 2, revised: March 25, 2020; Replaces FAQs dated March 16, 2020

## USAMRAA's Supplemental Guidance on Administrative Flexibilities for Grants and Cooperative Agreements in Response to COVID-19 Pandemic

On March 19, 2020 OMB issued Memorandum M-20-17, [Administrative Relief for Recipients and Applicants of Federal Financial Assistance Directly Impacted by the Novel Coronavirus \(COVID-19\) due to Loss of Operations](https://www.whitehouse.gov/wp-content/uploads/2020/03/M-20-17.pdf). The Department of Defense (DoD) also recently published Frequently Asked Questions (FAQs) (<https://basicresearch.defense.gov/COVID-19/Frequently-Asked-Questions/>). The United States Army Medical Research Acquisition Activity (USAMRAA) will apply, to the maximum extent possible, all the allowed exceptions to our financial awards, including allowance of costs. The following exceptions, aligned with the format in Memorandum M-20-17 and guidance

---



{ Z % } CE š • š • μ u ] š š š š Z v } ( š Z % } • š % } v % CE ] } % CE ] } CE } v % % CE š À v • ] }

11. Extension of currently approved indirect costs rates:

{ Z ] % } v š • v š ] μ š } μ • š Z μ CE CE v š o Ç % % CE } CE ] š v CE CE ] v š U } • ( š AE š U • ) CE ] % recover their indirect costs on Federal awards.

{ Z ] % } v š • v š Ç š š Z ] CE } P v ] v š P v Ç ( ) CE ] v ] CE š š Z • š μ • š } } CE š Ç μ • š CE CE AE š additional year without submission of an indirect cost proposal. The cognizant agency may also approve requests for an extension of the indirect cost rate proposal submission to finalize the current rates and establish future rates.

12. Extension of closeout:

{ Z ] % } v š • u • Ç u ] • Ç } v } ( v Ç % v ] v P ( ] v v ] o U % CE ( ) CE u v š Z š CE š Z ] CE š Z for the closeout of expired projects, provided that proper notice about the reporting delay is given by the grantee to the G { d Z ] • • Ç u ] š š ] v P o } • } μ š CE % } CE š • u Ç v } š AE } v Ç CE ( š CE š Z Á C

13. Extension of Single Audit submission.

{ / u % o u v š š š • ] v D r î i r í ó X

14. The COVID-19 pandemic has impacted the conduct of my DoD-supported human subjects research protocol. What can I do?

{ & } CE P μ ] [https://www.army.mil/index.cfm/collaborate/research\\_protections/hrpo/faqs](https://www.army.mil/index.cfm/collaborate/research_protections/hrpo/faqs)

í ñ X h Z K ' μ ] μ CE ] v P š Z K s / r í õ W v u ]

{ & } CE P μ ] [https://www.army.mil/assets/docs/orp/acuro/ACURO\\_Guidance\\_for\\_COVID-19.pdf](https://www.army.mil/assets/docs/orp/acuro/ACURO_Guidance_for_COVID-19.pdf)